The relationship between serum triglyceride levels and acute pancreatitis in an animal model and a 14-year retrospective clinical study

Qiyue Zhang, Mengbin Qin, Zhihai Liang, Huali Huang, Yongfeng Tang, Lingyan Qin, Zhenping Wei, Mengtao Xu and Guodu Tang

Background
Acute pancreatitis (AP), an inflammatory illness of the pancreas, is the leading cause of hospital admission for gastrointestinal illnesses in many countries [1]. Hypertriglyceridemia (HTG) is the second most common cause of acute pancreatitis, after gallstones, accounting for 10.36% of AP cases [2]. The etiology of gestational pancreatitis in particular is thought to be attributable to HTG in approximately 56% of patients [3]. The percentage of cases in which hypertriglyceridemic pancreatitis (HTGP) results in AP is rising globally [4, 5].

Introduction
Although many studies have concentrated on the relationship between AP etiology and HTG, the exact relationship between disease severity and HTG has not been fully confirmed, and the role of HTG in modulating AP disease course remains controversial [6]. Disease complications, such as renal failure, shock, infection, and mortality have been found in a number of studies to be higher in the HTG group than in controls, indicating that HTG exacerbates severe acute pancreatitis (SAP), resulting in systemic complications and an elevated SAP mortality rate [7, 8]. Kimura et al. also found that...
triglyceride (TG) levels were associated with a worsening of pancreatic injury in animal models, with extensive lipase activity and histological damage occurring in an experimental hyperlipidaemic pancreatitis model system [9, 10]. This led us to hypothesize that a similar pathophysiology may occur in the context of HTG-related pancreatitis. In addition, Tariq et al. found that a TG level ≥ 2.26 mmol/L on admission in AP patients was an independent predictor of the development of systemic and local complications, hospital length of stay, admission to the intensive care unit (ICU), and ICU length of stay [11]. Additional studies, however, found no relationship between TG levels and AP severity, rates of complications, amylase levels, or APACHE II and Ranson’s criteria score [12–14]. While these results are inconsistent with one another, they come from studies with small sample sizes potentially accounting for this discrepancy. We therefore conducted the present study with the aims of assessing the differences in the pancreas tissue damage between AP secondary to HTG and other forms of AP in rats, of assessing the clinical connection between AP disease course and variations in TG levels, and of ascertaining the role of elevated TG levels on the prognosis and severity of AP. To this end, we assessed a wide range of collected parameters in a series of 1681 patients from the First Affiliated Hospital of Guangxi Medical University over a 14-year period. We further classified AP patients into specific subgroups to investigate thoroughly the relationship of TG levels and AP severity, and we used animal models to gain mechanistic insights into the role of TG in pancreatitis-associated damage.

Materials and methods

Animal experiments

Four-week-old male SD rats (70–80 g) were obtained from the Experimental Medical Center of Guangxi Medical University. All rats were maintained in a temperature-controlled room (22 ± 1°C). Rats were divided into three groups at random (n = 6 per group): Control rats (NORMAL), rats with hypertriglyceridemic pancreatitis (HTGP), and rats with non-hypertriglyceridemic pancreatitis (NHTGP). The HTGP rats were fed a high fat diet, while the NORMAL rats and the NHTGP rats were fed a normal fat diet for 4 weeks. The high fat diet formula consisted of 15% lard, 2% cholesterol (Weijia, China), 0.2% sodium cholate (Weijia, China), and 82.8% normal fat diet (Kaoxieli, China) forage. After 4 weeks feeding, triglyceridemia levels were quantitated using blood samples collected from the posterior orbital plexus of all rats in this three groups tested by Hitachi 7600 automatic biochemical analyzer (Hitachi, Japan) in clinical laboratories of the First Affiliated Hospital of Guangxi Medical University. Detection method is GPO-PAP method by reagent kit for triglycerides test (Denuo, China). All the animals were fasted for 12 h prior to surgical operations. An AP model was established in the rats in HTGP and NHTGP groups via intraperitoneal injection of caerulein (50 μg/kg) (Sigma Aldrich, USA) every 1 h for 7 consecutive hours. Normal control rats received saline injections at the same time points. After 24 h, rats were euthanized [15]. Serum amylase levels were quantitated in EPS method (α-glucosaccharase) by reagent kit for α-amylase test (Denuo, China) using blood samples collected from the right atrium of all rats. Serum amylase levels were also tested by Hitachi 7600 automatic biochemical analyzer (Hitachi, Japan) in clinical laboratories of the First Affiliated Hospital of Guangxi Medical University. Pancreatic tissue samples were collected from all rats following euthanasia. A section of the pancreatic gland was fixed using 10% formalin, paraffin-embedded, and used for morphologic assessment by H&E staining. The degree of pancreatic injury was assessed by light microscopy based on the severity of edema, hemorrhage, inflammatory cell infiltration, and cell destruction. The pathologic scores of these samples were evaluated by a pathologist pursuant to Schmidt’s criteria on the severity of these conditions [6, 10]. TG levels, serum amylase, and pancreatic tissue histological scores were then compared among these three experimental groups.

Clinical study

Patients

In the clinical study, we collected clinical data from 2670 AP patients admitted between 1 June 2003 and 1 June 2016 to the First Affiliated Hospital of Guangxi Medical University. The diagnosis of AP was confirmed based on revised Atlanta Criteria prior to using subject data in the present study. A diagnosis of AP necessitated two of the following three attributes: (1) abdominal soreness; (2) serum lipase activity (reference range, 0–60 U/L) or amylase activity (reference range, 0–220 U/L) at least three times grander than the upper limit of normal; (3) typical facilities inspection of acute pancreatitis such as contrast-enhanced computed tomography (CECT) or less commonly magnetic resonance imaging (MRI) or transabdominal ultrasonography [4]. Patient exclusion criteria were: (1) Patients who were <18 years old or pregnant were excluded from this analysis; (2) patients diagnosed as possessing chronic pancreatitis were likewise eliminated.

Serum triglyceride gradation

Serum triglyceride levels were detected in a total of 1681 patients within 48 h of hospital admission. These 1681 AP patients were retrospectively parceled out into 4 groups, including a normal triglyceride group (serum TG levels of 0–1.7 mmol/L), [16] a mild hypertriglyceridemia group (serum TG levels of 1.7–5.6 mmol/L), a
moderate hypertriglyceridemia group (serum TG levels of 5.6–11.2 mmol/L), and a severe hypertriglyceridemia group (serum TG levels of ≥11.2 mmol/L).

**Data collection and clinical manifestations**
The biochemical parameters collected from patient datasets were obtained either upon the initial presentation or within 10 days of hospital admission. Organ dysfunction was defined as reported by the Atlanta classification; severe pancreatitis was diagnosed when there were indications of dysfunction in other organs [4]. Data were collected on the patients’ critical gestures at admission, including hemogram, blood biochemical parameters, and imaging results including those from CECT, MRI, or transabdominal ultrasonography. Baseline clinical characteristics from patients including age, gender, weight, height, body mass index (BMI), diabetes, levels of white blood cells (WBC), Serum lipase (LPS), amylase (AMY), calcium concentration (Ca²⁺), C-reactive protein (CRP), and glucose (GLU) determined within 48 h of admission were used for statistical analyses in this study. In addition, instances of pancreatic effusion, pancreatic pseudocyst, pancreatic necrosis, pancreatic abscess, abdominal compartment syndrome (ACS), acute respiratory distress syndrome (ARDS), kidney injury, hydropericardium, arrhythmia, pancreatic encephalopathy (PE), disseminated intravascular coagulation (DIC), sepsis, fungal infection, chronic pancreatitis, hyperglycemia, and hydrothorax, were recorded and compared among the 4 TG groups. Furthermore, a receiver operating characteristic (ROC) curve analysis was also implemented on the TG values to determine SAP.

**Statistical analyses**
Statistical analyses were conducted using SPSS v20.0 (Statistical Package for Social Sciences, Chicago, USA). Numerical data are expressed as the means ± SEM, and categorical variables are expressed as the means (ratios). For comparisons of continuous variables t-tests and ANOVA were used as appropriate. Categorical variables were evaluated using a χ² test, and Fisher’s exact test was used when the number of observations was < 5. Serum TG was evaluated by means of a receiver operating characteristic curve for selected cut-off points. *P < 0.05* was considered with statistically significance.

**Results**

**Animal experiments**
In our animal experiments, we observed markedly higher TG levels in rats in the HTGP group, which also had elevated serum amylase and pancreas histological scores relative to rats in the NHTGP group. The mean serum TG levels in the HTGP group were significantly elevated relative to the NHTGP group (*P < 0.05*) (Table 1). Similarly, pancreas histology scores were higher in HTGP rats relative to NHTGP rats, whereas serum amylase levels were significantly higher in both AP groups relative to normal controls (*all P < 0.05*; Table 1).

Pancreatic necrosis was not observed in any group, with negligible changes in pancreatic histology in the normal group. Both the HTGP and NHTGP groups had substantial evidence of pancreatic edema and inflammatory cells infiltration, acinar cells vacuoles, and hemorrhage. Rats in the HTGP group exhibited more substantial pancreatic impairment than did those in the NHTGP group (Fig. 1).

**Clinical study**

**Basic patient demographics**
Baseline patient demographics for patients divided based on TG levels are shown in Table 2.

This clinical study included 1681 AP patients; of these, 1018 (60.6%) had normal TG levels (0.92 ± 0.01 mmol/L), 434 (25.8%) had mild HTG levels (3.00 ± 0.05 mmol/L), 127 (7.6%) had moderate HTG levels (7.88 ± 0.13 mmol/L), and 102 (6.1%) had severe HTG levels (18.59 ± 0.57 mmol/L). Patients with mild, moderate, or severe HTG were more commonly male (61.5% vs. 79.9% vs. 82.7% vs. 81.4%, respectively; *P < 0.05*), younger (mean age in years 51.77 ± 0.55 vs. 45.88 ± 0.73 vs. 40.03 ± 0.88 vs 43.53 ± 1.04; *P < 0.05*), and fatter (mean BMI 22.43 vs. 23.86 vs. 26.77 vs. 25.71; *P < 0.05*) compared to patients with typical TG levels. Histories of diabetes mellitus (6.4% vs. 11.2% vs. 22.8% vs. 26.4%; *P < 0.05*) were also more common in HTG groups.

**Comparison of laboratory parameters upon admission among patients with different TG levels**
Some parameters, such as AMS, LPS, Ca²⁺, CRP, and GLU exhibited significant differences between groups (*P < 0.05*). Significant differences were not discovered in WBC, NEU values between the 4 groups (*P > 0.05*; Table 3).

**Clinical outcomes**
Table 4 shows the complications developed by all study patients with AP. In the four TG subgroups (normal to severe), pancreatic effusion was observed in 419 (43.3%), 237 (58.7%), 98 (79.7%), and 77 (78.6%) patients (*P < 0.05*). Pancreatic necrosis was the next most common complication (13.3% vs. 28.6% vs. 20.6% vs. 32.7%), followed by ACS (0.4% vs. 1.5% vs. 4.8% vs. 2.0%), ARDS (2.7% vs. 5.5% vs. 11.0% vs. 9.8%), acute renal failure (3.8% vs. 6.5% vs. 10.2% vs. 18.6%), DIC (0.5% vs. 0.2% vs. 1.6% vs. 2.9%), and hydrothorax (32.4% vs. 43.5% vs. 54.7% vs. 60.6%). No significant difference in the incidence of pancreatic pseudocyst, hydropericardium, arrhythmia, pancreatic encephalopathy, sepsis, fungal infection, chronic pancreatitis, or hyperglycemia were observed between these 4 groups (*P ≥ 0.05*).
No significant differences were noted in the development of mortality among these groups, as shown in Table 5. AP patients exhibited a higher frequency of severe AP with increasing TG levels (28.3% vs. 37.4% vs. 54.8% vs. 51.0%) ($P < 0.05$). Hospitalization expenses also increased as TG levels increased (30,186.21 ± 1664.03 vs. 33,345.25 ± 3035.53 vs. 38,210.34 ± 5658.28 vs. 48,336.83 ± 9338.23) ($P < 0.05$).

ROC analysis of TG levels to predict severe acute pancreatitis

TG levels on days 1–2, 3–4, 5–6, 7–8, and 9–10 were compared between the non-severe acute pancreatitis group (NSAP) and severe acute pancreatitis group (SAP). TG levels in SAP patients were much higher than in NSAP patients on days 1–6 post admission ($P < 0.05$; Table 6).

### Table 1 Triglyceride, Serum Amylase and Pancreatitis Histological Score in Rats of 3 Groups

|             | NORMAL ($n = 6$) | NHTGP ($n = 6$) | HTGP ($n = 6$) | $P$    |
|-------------|-----------------|----------------|---------------|--------|
| TG (mmol/L) | 0.99 ± 0.30     | 0.99 ± 0.30    | 3.11 ± 0.73   | < 0.05 |
| AMY(U/L)    | 1443.29 ± 61.39 | 1886.83 ± 84.78| 2119.00 ± 86.24| < 0.05 |
| Histological scores of pancreas | 0.00            | 4.50 ± 1.52    | 6.43 ± 1.27   | < 0.05 |

Fig. 1 Pancreatic Pathology. a, b Normal group pancreas sections; (c, d) Pancreas sections for rats in the NHTGP group. The space between pancreatic lobules was significantly wider than in normal control rats, with clear edema and a large number of alveolar cells were vacuolar; (e, f) In the HTGP group, a large number of inflammatory cells infiltrated and exudate were evident in the pancreatic parenchyma, with evidence of pancreatic parenchymal hemorrhage.
We therefore performed a ROC analysis of patient TG levels on days 1–6 in an effort to identify values predictive of SAP. The area under the ROC curve in the prediction of SAP on days 0–2, days 3–4, and days 5–6 was 0.609 vs. 0.742 vs. 0.614, with significance at all tested time points (P < 0.05). TG levels in Day 3–4 still have highest accuracy in predicting occurrence of SAP which is consistent with the conclusion. TG levels on day 3–4 (with a threshold value of 2.06 mmol/L) could be used to accurately predict SAP better than could values on any other day of hospitalization. (Table 7) The ROC curve showed that a TG level of 2.06 mmol/l on day 3–4 was the optimal cut-off value for predicting more severe AP disease, with a sensitivity and specificity of 65.7 and 80.6%, respectively (Fig. 2).

Reference range: TG: 0.3–1.7 mmol/l, AUC indicates area under ROC curve PPV: positive predictive value, NPV: negative predictive value.

Discussion

Our research showed that pancreatitis that is initiated through unrelated pathogenic pathways can still be exacerbated by elevated TG grades in animal models, and the SAP rate was increased with increasing HTG severity in a clinical setting, which indicate that HTG can aggravate pancreatic injury, and that HTG patients are more likely to suffer from more severe pancreatic injury and have a higher possibility of local and systemic complications following the initial disease presentation. TG levels are also positively correlated with the severity of AP. To our knowledge, this study is the first to use a combination of animal and clinical trials in an effort to establish the relationship between serum TG levels and AP severity.

In our animal study, we established an animal model of HTG and induced acute pancreatitis via intraperitoneal injection of cerulein in rodents to further explore the relationship between HTG and AP. We observed significantly increased serum amylase levels in rats in the HTGP group, and increased pancreatic tissue inflammation relative to the NHTGP group in our animal study, consistent with previous studies, [17] Higher mean serum TG levels in our HTGP group of rats is relative to the NHTGP group, which means we establish HTG animal models in rats. And this group also showed evidence of more substantial pancreatic histological damage. In clinical data, we found that HTGP patients had higher levels of biomarkers of severe pancreatitis than did their counterparts with normal TG levels, and that HTG patients are more likely to suffer from severe pancreatic injury and a higher possibility of local and systemic complications. Levels of serum TG were closely correlated with AP disease severity, although we did not

| Table 2 Baseline Characters of Patients Versus Serum Triglyceride |
|-----------------------------|-------------------|-------------------|-------------------|-------------------|
|                            | Normal TG         | Mild HTG          | Moderate HTG      | Severe HTG        |
| Sum                         | 1018 (60.6%)      | 434 (25.8%)       | 127 (7.6%)        | 102 (6.1%)        |
| Gender                      | 625 (61.5%)       | 346 (79.9%)       | 105 (82.7%)       | 83 (81.4%)        |
| Diabetes                    | 61 (6.4%)         | 45 (11.2%)        | 26 (22.9%)        | 24 (26.4%)        |
| Age (year)                  | 51.77 ± 0.55      | 45.88 ± 0.73      | 40.03 ± 0.88      | 43.53 ± 1.04      |
| Weight (kilogram)           | 61.01 ± 1.71      | 69.50 ± 3.54      | 108.68 ± 18.61    | 89.38 ± 17.02     |
| Height (centimeter)         | 162.70 ± 0.90     | 163.08 ± 0.71     | 166.02 ± 1.03     | 166.57 ± 0.90     |
| BMI (kg/m²)                 | 22.43 ± 0.18      | 23.86 ± 0.27      | 26.77 ± 0.62      | 25.71 ± 0.55      |

Reference ranges: TG, 0–1.7 mmol/l; WBC, 3.5–9.5 × 10⁹/L; NEU, 40–75%; AMS, 0–220 U/L; LPS, 0–60 U/L; Ca²⁺, 2.0–2.7 mmol/L; CRP, 0.00–5.00 mg/L; GLU, 3.9–6.1 mmol/L

| Table 3 Initial Laboratory Values of Patients in 48 Hours Versus Serum Triglyceride |
|-------------------------------|-------------------|-------------------|-------------------|
|                              | Normal TG         | Mild HTG          | Moderate HTG      |
| TG (mmol/L)                  | 0.92 ± 0.01       | 3.00 ± 0.05       | 7.88 ± 0.13       |
| WBC(10⁹/L)                   | 11.87 ± 0.20      | 12.14 ± 0.25      | 12.06 ± 0.39      |
| NEU(%)                       | 59.20 ± 1.13      | 61.33 ± 1.59      | 56.67 ± 3.26      |
| AMS(U/L)                     | 662.85 ± 24.68    | 339.05 ± 25.85    | 414.86 ± 58.78    |
| LPS(U/L)                     | 361.19 ± 17.11    | 190.27 ± 16.73    | 200.97 ± 40.53    |
| Ca²⁺(mmol/L)                 | 2.13 ± 0.00       | 2.11 ± 0.01       | 2.01 ± 0.02       |
| CRP (mg/L)                   | 74.33 ± 4.07      | 102.72 ± 8.37     | 169.60 ± 16.02    |
| GLU (mmol/L)                 | 8.11 ± 0.44       | 8.65 ± 0.37       | 28.26 ± 11.00     |

Reference ranges: TG, 0–1.7 mmol/l; WBC, 3.5–9.5 × 10⁹/L; NEU, 40–75%; AMS, 0–220 U/L; LPS, 0–60 U/L; Ca²⁺, 2.0–2.7 mmol/L; CRP, 0.00–5.00 mg/L; GLU, 3.9–6.1 mmol/L
observe any significant differences in ultimate prognosis. Importantly, the TG levels of AP patients on day 3–4 post-hospitalization could be used to accurately predict SAP (with a cut-off value of 2.06 mmol/L), suggesting that HTG can aggravate pancreatic injury.

In our clinical study, patients with mild, moderate, and severe TG levels were more likely to be younger and heavier than patients with normal TG levels. The incidence of diabetes has also been found to be much greater in patients with elevated TG levels relative to patients with normal TG levels [18]. TG levels are also a key diagnostic component of identifying patients with metabolic syndrome according to the International Diabetes Federation criteria [19]. Patients with hypertriglyceridemia have a host of associations such as obesity, differing diet including alcohol, and metabolic syndrome. After the trigger is pulled, metabolic syndrome may be associated with a pro-inflammatory state which may aggravate inflammation [20]. and the presence of metabolic syndrome at admission is connected with a higher risk of severe acute pancreatitis, as well as with an elevated mortality rate and longer ICU occupancy [11, 21, 22].

When assessing laboratory parameters of AP patients within 48 h of admission, we saw that calcium levels were significantly lower in patients with higher TG levels, and these patients also had elevated blood pressure and CRP consistent with previous work. Indeed, CRP is a common marker of disease severity with good prognostic accuracy for severe acute pancreatitis [23, 24]. Higher blood glucose is indicative of endocrine pancreatic insufficiency and develops more easily during or after AP [25]. Patients in the high-TG group had lower calcium levels, which may imply that more lipotoxicity occurs in patients with HTGP with higher TG levels, leading to a poor prognosis [26].

| Table 4 Clinical Manifestation of Patients Versus Serum Triglyceride |
|---------------------------------------------------------------|
| **Normal** | **Mild HTG** | **Moderate HTG** | **Severe HTG** | **χ²** | **P** |
| Pancreatic effusion | 419 (43.3%) | 237 (58.7%) | 98 (79.7%) | 77 (78.6%) | 101.78 | 0.000 |
| Pancreatic pseudocyst | 92 (9.5%) | 44 (10.6%) | 11 (9.0%) | 4 (4.1%) | 3.92 | 0.264 |
| Pancreatic necrosis | 129 (13.3%) | 84 (28.6%) | 49 (20.6%) | 32 (32.7%) | 69.74 | 0.000 |
| Pancreatic abscess | 15 (1.5%) | 10 (2.4%) | 6 (4.8%) | 4 (4.1%) | 7.74 | 0.035 |
| ACS | 4 (0.4%) | 6 (1.5%) | 6 (4.8%) | 2 (2.0%) | 16.81 | 0.001 |
| ARDS | 27 (2.7%) | 24 (5.5%) | 14 (11.0%) | 10 (9.8%) | 28.50 | 0.000 |
| Kidney injury | 39 (3.8%) | 28 (6.5%) | 13 (10.2%) | 19 (18.6%) | 42.04 | 0.000 |
| Hydropericardium | 12 (1.2%) | 6 (1.4%) | 3 (2.4%) | 0 (0%) | 2.35 | 0.468 |
| Arrhythmia | 7 (0.7%) | 3 (0.7%) | 2 (1.6%) | 0 (0%) | 2.06 | 0.577 |
| PE | 3 (0.3%) | 3 (0.7%) | 1 (0.8%) | 2 (2.0%) | 5.58 | 0.089 |
| DIC | 5 (0.5%) | 1 (0.2%) | 2 (1.6%) | 3 (2.9%) | 8.97 | 0.018 |
| Septicaemia | 2 (0.2%) | 2 (0.5%) | 1 (0.8%) | 1 (1.0%) | 4.14 | 0.181 |
| Fungal infection | 5 (0.5%) | 4 (0.9%) | 2 (1.6%) | 0 (0%) | 3.03 | 0.296 |
| Chronic pancreatitis | 18 (1.8%) | 8 (1.9%) | 2 (1.7%) | 0 (0%) | 1.348 | 0.740 |
| Hyperglycemia | 55 (5.6%) | 36 (8.7%) | 11 (9.6%) | 13 (14.0%) | 12.776 | 0.005 |
| Hydrothorax | 301 (32.4%) | 170 (43.5%) | 64 (54.7%) | 57 (60.6%) | 50.816 | 0.000 |

| Table 5 Severity and Outcomes of Patients Comparison Versus Serum Triglyceride |
|---------------------------------------------------------------|
| **Normal HTG** | **Patients** | **Comparison Versus Serum Triglyceride** |
|---------------------------------------------------------------|
| **Normal HTG** | **Mild HTG** | **Moderate HTG** | **Severe HTG** | **χ²** | **P** |
| SAP | 281 (28.3%) | 161 (37.4%) | 68 (54.8%) | 50 (51.0%) | 53.09 | 0.000 |
| Death | 67 (6.6%) | 40 (9.2%) | 10 (7.9%) | 11 (10.8%) | 4.50 | 0.212 |
| Expense | 30,186.21 ± 1664.03 | 33,345.25 ± 3035.53 | 38,210.34 ± 5658.28 | 48,336.83 ± 9338.23 | – | 0.020 |
being aware of potentially misleadingly low levels of amylase in patients with elevated TG levels.

Hypertriglyceridaemia has been found to be linked with severe AP by our study and others [28–30]. We observed more severe pancreatitis in the high TG group in this study, implying that higher TG levels are associated with poorer prognosis in patients with HTGP. The incidence of mortality and complications was assessed in patients with AP. In these four TG subgroups, pancreatic effusion was the most differentially present complication, followed by pancreatic necrosis, abdominal compartment syndrome, acute respiratory distress syndrome, acute renal failure, disseminated intravascular coagulation, and hydrothorax. Nor were there any significant differences in mortality. AP severity and hospitalization costs were both found to increase as patient TG levels increased. Several recent studies have found that HTG is a prognostic indicator of AP-related complications such as pancreatic necrosis, pertinacious SIRS, and the need for admission to the ICU [8, 11]. Previous work thus leaves it unclear as to whether elevated TG levels are a risk factor for AP morbidity, a driver of disease etiology, or some satellite phenomenon associated with AP progression. The relationship between lipotoxicity and TG levels still warrants further investigation.

Given the clear differences in clinical outcomes among patients with varying TG levels, it is important for clinicians to identify these high risk patients. Patients with HTG presenting with AP should undergo serum TG level measurements and should undergo more frequent clinical observation and active symptomatic treatment. Those patients who will go on to develop severe pancreatitis may therefore be able to be admitted to the intensive care unit more quickly, allowing for quicker access to needed care [31]. In the long term, metabolic syndrome can be addressed in these patients through lifestyle changes and pharmacological interventions [19]. For the treatment of HTGP, it is critical to rapidly reduce TG levels and block progression of SIRS [22]. New hypolipidemic therapy is needed urgently. In addition to plasmapheresis, The potential use of alternative medicine such as anabasis aretioides, lasianthera africana, rutin and curcumin were proved lowering TG levels rapidly, making them worthy and promising strategies for clinical implementation, especially for patients with moderate or severe HTG [32–34]. In summary, to improve patient outcomes, experienced clinicians should identify severe pancreatitis based on symptoms, clinical and laboratory markers and various scoring systems as soon as possible in patients by taking risk factors into account [35]. In conclusion, serum TG levels are closely correlated with AP disease severity. HTG can aggravate pancreatic injury, and HTG patients are more likely to suffer from more severe pancreatic injury and a higher possibility of local and systemic complications. While TG levels are positively correlated with the severity of AP, no significant differences were observed in terms of prognosis among groups with different TG levels. Importantly, patient TG levels on day 3–4 post-admission (with a cut-off threshold of 2.06 mmol/L) can be used to accurately predict SAP. Future efforts at targeted therapeutic intervention will be needed to effectively reduce the mortality associated with acute pancreatitis, and early clinical recognition is vital to provide such targeted treatment and reduce rates of complications [36].

Further exploration of both a superior predictive SAP index and hypolipidemic therapy are needed. While much work has been conducted to date aimed at promoting apprehension better understanding of the pathophysiology of AP patients and of the systemic inflammation that leads to organ failure and SIRS, there still remain many unanswered questions for subsequent investigations [37].

There are several limitations to the present study. For one, this study was retrospective, potentially introducing unintended bias. In addition, we were unable to conduct comparisons between any two groups within the study, and as such we were unable to assess long-term efficacy or disease recurrence. Further randomized controlled studies and experimental work will be needed to better

### Table 6 Different Values of TG in NSAP and SAP Cases on DAY 1–2, 3, 4, 5–7, and 9–10 (Mean ± SEM)

| Characteristic | NSAP | SAP | P   |
|---------------|------|-----|-----|
| TG, mmol/L    |      |     |     |
| DAY 1–2       | 2.53 ± 0.12 | 4.04 ± 0.23 | 0.000 |
| DAY 3–4       | 1.85 ± 0.27 | 4.35 ± 0.55 | 0.000 |
| DAY 5–6       | 2.65 ± 0.24 | 3.55 ± 0.32 | 0.041 |
| DAY 7–8       | 3.65 ± 1.13 | 3.68 ± 0.45 | 0.975 |
| DAY 9–10      | 2.31 ± 0.40 | 2.85 ± 0.34 | 0.515 |

### Table 7 Most Appropriate Cut-off Points of TG in the Prediction of SAP on DAY 1–2, 3, 4, and 5–6

| Characteristics | Cut-off Points | P   | AUC | Sensitivity | Specificity | Youden Index | PPV | NPV | Accuracy |
|----------------|---------------|-----|-----|-------------|-------------|--------------|-----|-----|----------|
| Day 1–2 TG     | 2.39          | 0.000 | 0.609 | 0.418       | 0.761       | 0.179        | 0.466| 0.723| 0.646    |
| Day 3–4 TG     | 2.06          | 0.000 | 0.742 | 0.657       | 0.806       | 0.463        | 0.793| 0.675| 0.727    |
| Day 5–6 TG     | 3.54          | 0.064 | 0.614 | 0.431       | 0.821       | 0.252        | 0.758| 0.524| 0.600    |
identify appropriate treatments for improving pancreatitis in patients such as those enrolled in the present study.

Conclusion

HTG can aggravate pancreatic injury, and HTG patients are more likely to suffer from more severe pancreatic injury and have a higher possibility of local and systemic complications. In addition, TG levels are positively correlated with the severity of AP. It is imperative to reduce TG levels rapidly and block progression of SIRS timely during the onset of acute pancreatitis.

Abbreviations

ACS: Abdominal compartment syndrome; AMY: Amylase; AP: Acute pancreatitis; ARDS: Acute respiratory distress syndrome; BMI: Body mass index; Ca2+: Calcium concentration; CECT: Contrast-enhanced computed tomography; CRP: C-reactive protein; DIC: Disseminated intravascular coagulation; GLU: Glucose; HTG: Hypertriglyceridemia; HTGP: Hypertriglyceridemic pancreatitis; ICU: Intensive care unit; LPS: Lipase; MRI: Magnetic resonance imaging; NHTGP: Non-hypertriglyceridemic pancreatitis; NSAP: Non-severe acute pancreatitis group; PE: Pancreatic encephalopathy; ROC: Receiver operating characteristic; SAP: Severe acute pancreatitis; SIRS: Systemic inflammatory response syndrome; TG: Triglyceride; WBC: White blood cells

Acknowledgments

The authors thank all officials of Medical Record Department in the First Affiliated Hospital, Guangxi Medical University.

Authors’ contributions

QZ and MQ designed the study; ZL, HL, YT, LQ, ZW and MX collected biochemical data; QZ and MQ drafted the manuscript. GT is the project leader of this research. All authors read and approved the final manuscript.

Funding

This work was supported from the National Natural Science Foundation of China (No. 81260087), National Natural Science Foundation of China (No. 81560111) and National Natural Science Foundation of Guangxi Zhuang Autonomous Region (No. 2013GXNSFAA019186).

Availability of data and materials

The datasets during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The study was approved by the Ethics Committee of the First Affiliated Hospital, Guangxi Medical University.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Department of Gastroenterology, First Affiliated Hospital, Guangxi Medical University, Nanning 530021, Guangxi, China. 2Department of Gastroenterology, Second Affiliated Hospital, Guangxi Medical University, Nanning 530007, Guangxi, China.

Received: 2 May 2019 Accepted: 30 September 2019

Published online: 23 October 2019

References

1. Vipperla K, Somerville C, Furlan A, Koutroupakis E, Saul M, Chennat J, Rabinovitz M, Whitcomb DC, Silvia A, Papachristou G, Yadav D. Clinical profile and natural course in a large cohort of patients with hypertriglyceridemia and pancreatitis. J Clin Gastroenterol. 2017;51:77–85.
2. Zheng Y, Zhou Z, Li H, Li J, Li A, Ma B, Zhang T, Liao Q, Ye Y, Zhang Z, et al. A multicenter study on etiology of acute pancreatitis in Beijing during 5 years. Pancreas. 2015;44:409–14.
3. Chang CC, Hsieh YY, Tsai HD, Yang TC, Yeh LS, Hsu TY. Acute pancreatitis in pregnancy: Zhonghua Yi Xue Za Zhi (Taipei). 199861;85–92.
4. Banks PA, Bollen TL, Dervenis C, Gossen HG, Johnson CD, Sarr MG, Tsiotos GG, Vege SS. Classification of acute pancreatitis–2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62:102–11.
5. Tai WP, Lin XC, Liu H, Wang CH, Wu J, Zhang NW, Chen W. A retrospective research of the characteristic of Hypertriglyceridemic pancreatitis in Beijing, China. Gastroenterol Res Pract. 2016;2016:6263095.
6. Wu C, Zou L, Shi S, Tong Z, Shen X, Yang D, Ke L, Li W, Li J. The role of hypertriglyceridemia for acute kidney injury in the course of acute pancreatitis and an animal model. Pancreatology. 2017;17:561–6.
7. Deng LH, Xue P, Xia Q, Yang XN, Wan MH. Effect of admission hypertriglyceridemia on the episodes of severe acute pancreatitis. World J Gastroenterol. 2008;14:4558–61.
8. Wan J, He W, Zhu Y, Zhi Y, Zeng H, Liu P, Xia L, Lu N. Stratified analysis and clinical significance of elevated serum triglyceride levels in early acute pancreatitis: a retrospective study. Lipids Health Dis. 2017;16:124.
9. Hofbauer B, Friess H, Weber A, Baczko K, Kissing P, Schilling M, Uhl W, Dervenis C, Buchler MW. Hyperlipaemia intensifies the course of acute oedematous and acute necrotising pancreatitis in the rat. Gut. 1999;38:763–8.
10. Schmidt J, Rattner DW, Lewandowski K, Compton CC, Mandavalli U, Knoefel WT, Warshaw AL. A better model of acute pancreatitis for evaluating therapy. Ann Surg. 1992;215:44–56.
11. Tariq H, Gaduputi V, Peralta R, Abbas N, Nayudu SK, Thet P, Zaw T, Hui S, Chilimuri S. Serum triglyceride level: a predictor of complications and outcomes in acute pancreatitis? Can J Gastroenterol Hepatol. 2016;2016:6198047.
12. Balachandra S, Virlos IT, King NK, Siriwardana HP, France MW, Siriwardena AK. Hyperlipidaemia and outcome in acute pancreatitis. Int J Gastroenterol. 2015;56:102.
13. Hofbauer B, Friess H, Weber A, Baczko K, Kissing P, Schilling M, Uhl W, Dervenis C, Buchler MW. Hyperlipaemia intensifies the course of acute oedematous and acute necrotising pancreatitis in the rat. Gut. 1999;38:763–8.
14. Schmidt J, Rattner DW, Lewandowski K, Compton CC, Mandavalli U, Knoefel WT, Warshaw AL. A better model of acute pancreatitis for evaluating therapy. Ann Surg. 1992;215:44–56.
15. Tariq H, Gaduputi V, Peralta R, Abbas N, Nayudu SK, Thet P, Zaw T, Hui S, Chilimuri S. Serum triglyceride level: a predictor of complications and outcomes in acute pancreatitis? Can J Gastroenterol Hepatol. 2016;2016:6198047.
16. Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, Stalenhoef AF. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:969–89.

17. Patel K, Trivedi RN, Duragampudi C, Noel P, Cline RA, DeLany JP, Navina S, Singh VP. Lipolysis of visceral adipocyte triglyceride by pancreatic lipases converts mild acute pancreatitis to severe pancreatitis independent of necrosis and inflammation. Am J Pathol. 2015;185:808–19.

18. Albal O, Roman D, Frandes M. Hypertriglyceridemia, an important and independent risk factor for acute pancreatitis in patients with type 2 diabetes mellitus. Ther Clin Risk Manag. 2017;13:515–22.

19. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415–28.

20. Catalano R, Cuffari B, Italia A, Marotta F. Exploring the metabolic syndrome: nonalcoholic fatty pancreas disease. World J Gastroenterol. 2016;22:7660–75.

21. Mikolasevic I, Milic S, Orlic L, Poropat G, Jakopcic I, Kristo N, Stimac D. Metabolic syndrome and acute pancreatitis. Eur J Intern Med. 2016;32:79–83.

22. Gonzalez-Moreno EJ, Gonzalez-Gonzalez JA, Garza-Gonzalez E, Bosques-Padilla FJ, Maldonado-Garza HJ. Elevated serum triglycerides associated with systemic inflammatory response syndrome and persistent organ failure in acute pancreatitis. Am J Gastroenterol. 2016;111:149.

23. Shah AP, Mourad MM, Bramhall SR. Acute pancreatitis: current perspectives on diagnosis and management. J Inflamm Res. 2018;11:77–85.

24. Seouli SM, Oertli D, Nebiker CA. Laboratory markers predicting severity of acute pancreatitis. Crit Rev Clin Lab Sci. 2015;52:273–83.

25. Vujasinovic M, Tepes B, Makuc J, Rudolf S, Zaiman V, Seruga M, Birsar V. Pancreatic exocrine insufficiency, diabetes mellitus and serum nutritional markers after acute pancreatitis. World J Gastroenterol. 2014;20:18432–8.

26. Wang SH, Chou YC, Shangkuan WC, Wei KY, Pan YH, Lin HC. Relationship between plasma triglyceride level and severity of Hypertriglyceridemic pancreatitis. PLoS One. 2016;11:e0163984.

27. Melnick S, Nazir S, Gish D, Aryan MR. Hypertriglyceridemic pancreatitis associated with confounding laboratory abnormalities. J Community Hosp Intern Med Perspect. 2016;6:808.

28. Zhang R, Deng L, Lin T, Zhu P, Shi N, Jiang K, Li L, Yang X, Guo J, Yang X, et al. Hypertriglyceridemia-associated acute pancreatitis: diagnosis and impact on severity. HPB (Oxford). 2019;21(9):1240–9.

29. Jo SI, Chang JH, Kim TH, Kim CW, Kim JK, Han SW. Subsets associated with developing acute pancreatitis in patients with severe hypertriglyceridemia and the severity of pancreatitis. Pancreatology. 2019;19(6):795–800.

30. Stefanutti C, Labbadia G, Morelli C. Severe hypertriglyceridemia-related acute pancreatitis. Ther Apher Dial. 2013;17:130–7.

31. Garg R, Rustagi T. Management of Hypertriglyceridemia Induced Acute Pancreatitis. Biomed Res Int. 2018;2018:1–12.

32. Nwidu LL, Teme RE. Hot aqueous leaf extract of Lasianthera africana (Icacinaceae) attenuates rifampicin-isoniazid-induced hepatotoxicity. J Integr Med. 2018;16:263–72.

33. Farid O, Khalilouk F, Akdad M, Breuer A, Owen RW, Eddouks M. Phytochemical characterization of polyphenolic compounds with HPLC-DAD-ESI-MS and evaluation of lipid-lowering capacity of aqueous extracts from Saharan plant anabasis aethiopica (Coss & Moq.) in normal and streptozotocin-induced diabetic rats. J Integr Med. 2018;16:185–91.

34. Manzoni AG, Pasos DF, da Silva JLG, Bernardes VM, Bremm JM, Jantsch NH, de Oliveira JS, Marin TR, de Andrade CM, Leal DDR. Rutin and curcumin reduce inflammation, triglyceride levels and ADA activity in serum and immune cells in a model of hyperlipidemia. Blood Cells Mol Dis. 2019;76:13–21.

35. Forsmark CE, Vege SS, Wilcox CM. Acute Pancreatitis. N Engl J Med. 2016;375:1972–81.

36. Charlesworth A, Steger A, Crook MA. Acute pancreatitis associated with severe hypertriglyceridaemia: a retrospective cohort study. Int J Surg. 2015;23:23–7.

37. Singh P, Garg PK. Pathophysiological mechanisms in acute pancreatitis: current understanding. Indian J Gastroenterol. 2016;35:153–66.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions